Medtronic plc announced that the U.S. Food and Drug Administration cleared its Stealth AXiS surgical system for use in cranial and ear, nose, and throat (ENT) procedures on March 27, 2026. The clearance follows an earlier approval on February 13, 2026 that opened the platform for spine surgeries, extending the system’s indications to complex cranial and ENT operations.
The Stealth AXiS platform combines advanced navigation, robotics, and AI‑enabled capabilities into a single integrated system. “With the Stealth AXiS™ surgical system, we are bringing together advanced navigation, robotics, and AI‑enabled capabilities within the AiBLE™ smart ecosystem to support surgeons with deeper insights across the surgical workflow,” said Michael Carter, Senior Vice President and President of Medtronic Cranial & Spinal Technologies.
The cranial and ENT surgical navigation and robotics market is estimated at roughly $15 billion. By adding these indications, Medtronic can leverage its existing platform across three high‑value specialties, creating cross‑sell opportunities and reducing development costs. The company’s strategy to offer a unified, AI‑driven system positions it against competitors such as Johnson & Johnson and Globus Medical in the spine arena and other navigation vendors in the cranial and ENT space.
The new clearance is expected to accelerate revenue growth by expanding the addressable market for the Stealth AXiS platform. “For complex brain surgeries, the more information you have, the better decisions you can make. Pre‑operative planning with tools like tractography may help surgeons enhance surgical efficiency and support better patient outcomes,” said Dr. Michael Ivan, neurosurgeon at the University of Miami Health System.
Medtronic’s recent financial performance provides a solid foundation for this expansion. In Q4 FY2024, the company reported worldwide revenue of $8.589 billion, a 0.5% increase year‑over‑year, and a non‑GAAP diluted EPS of $1.46, beating analyst expectations. The company’s full‑year 2024 revenue of $32.364 billion grew 3.6% year‑over‑year, underscoring its ability to generate consistent top‑line growth while introducing new product lines.
“The Stealth AXiS™ system represents a meaningful step forward in how we think about navigation and robotics working together. One of the biggest challenges in spine surgery has been understanding and responding to how the spine moves during a procedure. The Stealth AXiS™ system gives surgeons real‑time visibility into that motion, helping us more consistently achieve our surgical plan without interrupting workflow. To me, this is truly game‑changing technology,” said Ronald A. Lehman, Jr., M.D., a paid consultant to Medtronic.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.